Direct comparison
IIT vs. Sponsor-Led Trial: Key Differences
Investigator-initiated trials vs. sponsor-led studies: who holds the IND/IDE, funding source, protocol ownership, and administrative burden compared.
Side-by-side comparison
| Dimension | Investigator-Initiated Trial (IIT) | Sponsor-Led (Industry) Study |
|---|---|---|
| Who originates the protocol | The investigator designs and authors the protocol | The company designs the master protocol, applied across all sites |
| Typical funding source | Institutional/foundation funds, federal grants, or an industry investigator-initiated study (IIS) grant | The company's own R&D budget |
| FDA sponsor of record (IND/IDE holder) | The investigator, as sponsor-investigator (21 CFR 312.3) | The company |
| FDA Form 1571 (IND cover sheet) | Signed by the sponsor-investigator, in the sponsor capacity | Signed by the company as sponsor |
| FDA Form 1572 (Statement of Investigator) | Signed by the same sponsor-investigator, in the investigator capacity | Signed separately by each site's principal investigator |
| Protocol amendment authority | Investigator submits and controls amendments | Company's regulatory/clinical operations function controls amendments |
| Regulatory/administrative burden | Concentrated on the investigator and their institution, with limited dedicated infrastructure per trial | Absorbed by dedicated company regulatory affairs, pharmacovigilance, and clinical operations departments |
| Safety reporting responsibility (21 CFR 312.32) | Sponsor-investigator personally responsible for expedited IND safety reports | Company's pharmacovigilance function manages expedited reporting |
| Typical trial scope | Single-site or small multi-site academic collaboration | Often large, multi-site, and multinational |
| Data ownership / publication rights | Typically retained by the investigator and institution, even with industry IIS funding | Typically retained by the company, often with contractual publication review rights |
| Monitoring responsibility | Investigator/institution arranges monitoring (internally or via a contracted third party) | Company's own CRA/CRO monitoring infrastructure |
Common questions
FAQ
Can an investigator-initiated trial be funded by a pharmaceutical company?+
Yes. This is common practice via an investigator-initiated study (IIS) grant, where a company funds a trial proposed and designed by an academic investigator. The funding relationship does not by itself change who holds the FDA sponsor role — the investigator remains the sponsor-investigator (and IND/IDE holder) unless the parties specifically agree otherwise.
Who is the FDA sponsor of record in an investigator-initiated trial?+
The investigator, acting as a sponsor-investigator under 21 CFR 312.3 — an individual who both initiates and takes regulatory responsibility for the trial (the sponsor role) and personally conducts it (the investigator role), and who holds the IND or IDE.
Does an investigator-initiated trial have less regulatory burden than a sponsor-led one?+
The trial itself doesn't have less regulatory burden — the same FDA requirements apply either way. What differs is who carries it: a company running a sponsor-led study has dedicated regulatory affairs and pharmacovigilance departments built for that purpose, while an investigator-initiated trial concentrates the same IND/IDE maintenance, safety reporting, and monitoring obligations on the investigator and their institution, which typically have far less dedicated infrastructure per trial.
Can a CRO run an investigator-initiated trial?+
An investigator or institution can contract a CRO (or individual functions of one) to perform specific tasks such as monitoring or data management, but the sponsor-investigator retains the FDA sponsor role and its regulatory responsibilities — contracting out tasks doesn't transfer the IND/IDE holder designation.
